Metraipolis › archive › dc_f7b75aaa294f

Label-free affinity screening, design and synthesis of inhibitors targeting the Mycobacterium tuberculosis L-alanine dehydrogenase — Europe PMC PMID:36395154

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/36395154
DOI
10.1371/journal.pone.0277670
License (as archived)
CC0-1.0
Archived
2026-10-15T16:01:00.509Z
SHA-256 of the archived text
6292193bb5cbf8f935b96612347666231ce2af06e8d12e35e12cb40cf7d20a83
Stable URL of this page
https://metraipolis.com/documento/dc_f7b75aaa294f

How to cite

Label-free affinity screening, design and synthesis of inhibitors targeting the Mycobacterium tuberculosis L-alanine dehydrogenase — Europe PMC PMID:36395154 — Europe PMC (en), https://europepmc.org/article/MED/36395154 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_f7b75aaa294f (Metraipolis archive dc_f7b75aaa294f, sha256 6292193bb5cbf8f935b96612347666231ce2af06e8d12e35e12cb40cf7d20a83)
BibTeX
@misc{dcf7b75aaa294f,
  title = {Label-free affinity screening, design and synthesis of inhibitors targeting the Mycobacterium tuberculosis L-alanine dehydrogenase — Europe PMC PMID:36395154},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/36395154},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_f7b75aaa294f; sha256 6292193bb5cbf8f935b96612347666231ce2af06e8d12e35e12cb40cf7d20a83},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/36395154. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

The ability of Mycobacterium tuberculosis (Mtb) to persist in its host may enable an evolutionary advantage for drug resistant variants to emerge. A potential strategy to prevent persistence and gain drug efficacy is to directly target the activity of enzymes that are crucial for persistence. We present a method for expedited discovery and structure-based design of lead compounds by targeting the hypoxia-associated enzyme L-alanine dehydrogenase (AlaDH). Biochemical and structural analyses of AlaDH confirmed binding of nucleoside derivatives and showed a site adjacent to the nucleoside binding pocket that can confer specificity to putative inhibitors. Using a combination of dye-ligand affinity chromatography, enzyme kinetics and protein crystallographic studies, we show the development and validation of drug prototypes. Crystal structures of AlaDH-inhibitor complexes with variations at the N6 position of the adenyl-moiety of the inhibitor provide insight into the molecular basis for the specificity of these compounds. We describe a drug-designing pipeline that aims to block Mtb to proliferate upon re-oxygenation by specifically blocking NAD accessibility to AlaDH. The collective approach to drug discovery was further evaluated through in silico analyses providing additional insight into an efficient drug development strategy that can be further assessed with the incorporation of in vivo studies.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2022 (prima pubblicazione 2022-11-17).
Identificativi: PMID 36395154 · PMCID PMC9671377 · DOI 10.1371/journal.pone.0277670.
Descrittori MeSH principali: Mycobacterium tuberculosis; Alanine Dehydrogenase.
Pagina: https://europepmc.org/article/MED/36395154 — https://doi.org/10.1371/journal.pone.0277670. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-15T15:25:26.721Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.